Showing results (121-130 of 177) with videos related to

Sort By:
Pageof 18
Antiviral Therapy|October 9, 2009
Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trialAndrea M Woltman, Martijn J Ter Borg, Rekha S Binda, et al.
Blood|July 2, 2002
MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursorsAllan J Masterson, Claudia C Sombroek, Tanja D De Gruijl, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 14, 2002
The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyriaJohan W Jonker, Marije Buitelaar, Els Wagenaar, et al.
Journal of Leukocyte Biology|September 9, 2006
A CD34(+) human cell line model of myeloid dendritic cell differentiation: evidence for a CD14(+)CD11b(+) Langerhans cell precursorSaskia J A M Santegoets, Allan J Masterson, Pieter C van der Sluis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2007
Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patientsBarbara G Molenkamp, Paul A M van Leeuwen, Sybren Meijer, et al.
Blood|July 16, 2008
A role for multidrug resistance protein 4 (MRP4; ABCC4) in human dendritic cell migrationRieneke van de Ven, George L Scheffer, Anneke W Reurs, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|February 19, 2002
Tissue distribution and induction of human multidrug resistant protein 3George L Scheffer, Marcel Kool, Marcel de Haas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2007
Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinomaJohan W Molling, Jacqueline A E Langius, Johannes A Langendijk, et al.
Cancer Research|July 13, 2011
Potent antitumor immunity generated by a CD40-targeted adenoviral vaccineBasav N Hangalapura, Dinja Oosterhoff, Jan de Groot, et al.
Pageof 18